- Conditions
- Varicella
- Interventions
- TNM005, Placebo, VariZIG
- Drug
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immunologic Deficiency Syndromes
- Interventions
- GC5107
- Biological
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 10
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Interventions
- US-ATG-F, Placebo
- Biological
- Lead sponsor
- Neovii Biotech
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 20 more
- Conditions
- Infant Botulism, Botulism
- Interventions
- botulism immune globulin
- Drug
- Lead sponsor
- California Department of Health Services
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Kawasaki Disease, Coronary Aneurysm
- Interventions
- Doxycycline, Placebo
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more
- Conditions
- Anti-Hepatitis A Antibody Levels in Heathy Subjects
- Interventions
- Immune Globulin (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Down Syndrome, Regression
- Interventions
- Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Aurora, Colorado
- Conditions
- Post-polio Syndrome
- Interventions
- Flebogamma® 5% DIF, Placebo
- Biological · Drug
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Primary Immune Deficiency
- Interventions
- GC5107
- Biological
- Lead sponsor
- GC Biopharma Corp
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more
- Conditions
- Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease, PANDAS
- Interventions
- Gamunex Intravenous Immunoglobulin, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 4 Years to 13 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Smallpox Vaccine Adverse Reaction
- Interventions
- ACAM2000
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Altamonte Springs, Florida
- Conditions
- COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
- Biological · Other · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 593 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 18
- States / cities
- Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Octagam 10%
- Biological
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 50 Years to 84 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Cypress, California • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Hepatitis B
- Interventions
- glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
- Procedure · Biological
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
- Other · Drug · Biological + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
- Interventions
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Alzheimer's Disease
- Interventions
- Albumin 5%, Albumin 20%, Immunoglobulin
- Biological
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 22
- States / cities
- Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
- Conditions
- Lung Transplant Rejection
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- John F. McDyer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Influenza
- Interventions
- Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 11
- States / cities
- San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- COVID, SARS-CoV2 Infection, Covid19
- Interventions
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
- Biological · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Mather, California • Palo Alto, California + 13 more
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
- Interventions
- Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, G-csf, Mesna, CliniMACS, ATG (rabbit), Blinatumomab, TCRα/β+, CD19+, CD45RA-depleted DLI
- Drug · Biological · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee